181 related articles for article (PubMed ID: 36553620)
1. Genetic Polymorphisms of Cytochromes P450 in Finno-Permic Populations of Russia.
Dzhaubermezov M; Ekomasova N; Mustafin R; Gabidullina L; Galimova Y; Nurgalieva A; Valova Y; Prokofyeva D; Khusnutdinova E
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553620
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
3. Cytochromes P450 and cancer.
Kaminsky LS; Spivack SD
Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
[No Abstract] [Full Text] [Related]
4. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan.
Mirzaev KB; Sychev DA; Ryzhikova KA; Konova OD; Mammaev SN; Gafurov DM; Shuev GN; Grishina EA; Sozaeva ZA
Genet Test Mol Biomarkers; 2017 Dec; 21(12):747-753. PubMed ID: 29023140
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
Ingelman-Sundberg M; Johansson I; Persson I; Yue QY; Dahl ML; Bertilsson L; Sjöqvist F
Pharmacogenetics; 1992 Dec; 2(6):264-71. PubMed ID: 1306127
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
7. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
8. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
Masimirembwa CM; Hasler JA
Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
15. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians.
Gra O; Mityaeva O; Berdichevets I; Kozhekbaeva Z; Fesenko D; Kurbatova O; Goldenkova-Pavlova I; Nasedkina T
Genet Test Mol Biomarkers; 2010 Jun; 14(3):329-42. PubMed ID: 20373852
[TBL] [Abstract][Full Text] [Related]
16. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
17. Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples.
Dlouhá L; Adámková V; Šedová L; Olišarová V; Hubáček JA; Tóthová V
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681777
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the cytochromes P450.
Daly AK
Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
[TBL] [Abstract][Full Text] [Related]
20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
